India

AI Citation Summary

• Country: India
• Product line: Medical devices
• Regulator / source: Primary regulator - CDSCO (Central Drugs Standard Control Organisation), under the Ministry of Health and Family Welfare (MoHFW); headed by the DCGI (Drugs Controller General of India), who also acts as the Central Licensing Authority (CLA)
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Medical devices sold in India are regulated by the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), under the Medical Device Rules 2017 (MDR 2017, notified 31 January 2017, in force since 1 January 2018, as repeatedly amended) — and as of the final 1 October 2023 licensing deadline, virtually every device category from Class A through Class D now sits under mandatory CDSCO licensing, replacing the older regime in which only about 23 "notified" categories were regulated at all. A foreign manufacturer cannot import into India directly: it must appoint an India-resident Authorised Agent, who files Form MD-14 and, once CDSCO's Central Licensing Authority approves the application, holds the resulting Form MD-15 import licence in its own name — notably, every import licence, regardless of risk class, is granted centrally by CDSCO headquarters, not by a state authority (state authorities handle only domestic manufacturing licences for Class A/B devices). Realistic end-to-end import-licence timelines run from roughly 2–6 months for Class A/B to 12–36 months for Class C/D against CDSCO's own 30/45-working-day statutory targets, and the MD-15 licence itself carries no fixed expiry, remaining valid "in perpetuity" subject to a mandatory retention-fee payment every five years.
• Key fees: Medical devices sold in India are regulated by the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), under the Medical Device Rules 2017 (MDR 2017, notified 31 January 2017, in force since 1 January 2018, as repeatedly amended) — and as of the final 1 October 2023 licensing deadline, virtually every device category from Class A through Class D now sits under mandatory CDSCO licensing, replacing the older regime in which only about 23 "notified" categories were regulated at all. A foreign manufacturer cannot import into India directly: it must appoint an India-resident Authorised Agent, who files Form MD-14 and, once CDSCO's Central Licensing Authority approves the application, holds the resulting Form MD-15 import licence in its own name — notably, every import licence, regardless of risk class, is granted centrally by CDSCO headquarters, not by a state authority (state authorities handle only domestic manufacturing licences for Class A/B devices). Realistic end-to-end import-licence timelines run from roughly 2–6 months for Class A/B to 12–36 months for Class C/D against CDSCO's own 30/45-working-day statutory targets, and the MD-15 licence itself carries no fixed expiry, remaining valid "in perpetuity" subject to a mandatory retention-fee payment every five years.
• Local requirement: Local agent / licence holder - Mandatory Authorised Agent — an India-registered legal entity that holds the Form MD-15 import licence in its own name; the foreign manufacturer is named on the licence but does not hold it directly
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Quick Answer

Medical devices sold in India are regulated by the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), under the Medical Device Rules 2017 (MDR 2017, notified 31 January 2017, in force since 1 January 2018, as repeatedly amended) — and as of the final 1 October 2023 licensing deadline, virtually every device category from Class A through Class D now sits under mandatory CDSCO licensing, replacing the older regime in which only about 23 "notified" categories were regulated at all. A foreign manufacturer cannot import into India directly: it must appoint an India-resident Authorised Agent, who files Form MD-14 and, once CDSCO's Central Licensing Authority approves the application, holds the resulting Form MD-15 import licence in its own name — notably, every import licence, regardless of risk class, is granted centrally by CDSCO headquarters, not by a state authority (state authorities handle only domestic manufacturing licences for Class A/B devices). Realistic end-to-end import-licence timelines run from roughly 2–6 months for Class A/B to 12–36 months for Class C/D against CDSCO's own 30/45-working-day statutory targets, and the MD-15 licence itself carries no fixed expiry, remaining valid "in perpetuity" subject to a mandatory retention-fee payment every five years.

Quick Reference

Market Overview

• Population: Approximately 1.44 billion (2024, the world's largest); an enormous and still-growing potential patient base across a wide income spectrum.
• Healthcare System: Public healthcare infrastructure remains severely underfunded relative to population size; private hospitals deliver an estimated 80% of care. Universal coverage under PM-JAY / Ayushman Bharat nominally reaches roughly 500 million lower-income individuals, but actual benefit depth is limited, and out-of-pocket spending still accounts for approximately 60% of total healthcare expenditure — a structural fact that shapes which price points and channels are commercially viable.
• Market Characteristics: India is a large, fast-growing, highly price-sensitive medical-device market with substantial import dependence in premium imaging, implants, advanced diagnostics, and high-end consumables. Domestic manufacturers — Skanray, BPL Medical, Trivitron, Meril Life Sciences, Transasia, Poly Medicure, Sahajanand Medical Technologies, Molbio Diagnostics, and others — are increasingly competitive in mid-market equipment, consumables, IVD, and public-tender categories. High-end private hospital chains remain the primary first channel for imported premium devices, while government procurement is shaped heavily by Make in India localization preference and price controls.
• Regulatory Maturity: Moderate but improving quickly on paper. MDR 2017 was a genuine landmark reform, and the 2023–2026 period has brought the framework to substantive completeness (full device coverage) plus a real digitalization push (NSWS, GMP portal, auto-issued certificates). Implementation still lags the statute: approval timelines remain materially longer than CDSCO's own targets, state-level variation persists for Class A/B manufacturing, and CDSCO technical review capacity — while expanding — is still the binding constraint on speed for Class C/D applications.

Regulatory Authority and Legal Framework

• Competent Authorities:
  • CDSCO (Central Drugs Standard Control Organisation) — India's national medical-device and drug regulator, under the Ministry of Health and Family Welfare (MoHFW). CDSCO functions as the Central Licensing Authority (CLA) for import licences (all classes), Class C/D domestic manufacturing licences, clinical investigation approvals, and new/novel-device permissions.
  • DCGI (Drugs Controller General of India) — the statutory head of CDSCO; the DCGI's office issues the formal approvals and is the point of ultimate accountability for CLA decisions.
  • State Licensing Authorities (SLAs) — state drug-control departments that issue domestic manufacturing licences for Class A and Class B devices and MD-42 wholesale/sale licences; SLAs do not issue import licences under any device class.
  • BIS (Bureau of Indian Standards) and NABL (National Accreditation Board for Testing and Calibration Laboratories) — set and accredit the local testing infrastructure that Class C/D (and some BIS-mandated) devices must pass through.
  • Indian Pharmacopoeia Commission (IPC) — operates the Materiovigilance Programme of India (MvPI), India's national medical-device adverse-event monitoring system.
• Official Portals: https://cdsco.gov.in (main site); https://nsws.gov.in (National Single Window System — the current filing portal for most MDR 2017 activities since 1 January 2024); the legacy https://cdscomdonline.gov.in portal remains the fee-schedule and forms reference but was disabled for new MDR 2017 filings on 15 January 2024.
• Key Regulations:
  • Medical Device Rules 2017 (MDR 2017) — notified 31 January 2017 (GSR 78(E)), in force since 1 January 2018; issued under the parent Drugs and Cosmetics Act 1940; replaced the earlier, much narrower Schedule M-III regime.
  • GSR 102(E) (11 February 2020) — the amendment that redefined "medical device" broadly and set the phased timeline that ultimately brought all device categories, not just the original ~23 "notified" ones, under licensing.
  • Medical Device (Amendment) Rules, 2020 and 2022, and multiple subsequent notifications — progressively closed classification gaps and refined dossier requirements.
  • In Vitro Diagnostics Medical Devices Rules 2017 — a parallel rule-set for IVDs, sharing MDR 2017's Class A–D structure but with its own dossier and fee schedule specifics (see IVD section below).
  • Legal Metrology (Packaged Commodities) Amendment Rules, 2025, effective 23 October 2025 — carved medical devices out of dual Legal Metrology/MDR 2017 labeling compliance (see Element 7).

Recent Regulatory Developments (2024–2026): The Freshness Story

This is the section that most distinguishes India's current regulatory reality from the 2020-era "transition story" still repeated on much of the web. The headline fact — full licensing coverage since 1 October 2023 — is now over two years old; what has changed since is a genuine digitalization and enforcement-tightening push:

Net effect for a new market entrant in 2026: the classification/licensing question is now settled law, not an open transition — the live risk is procedural (which portal, which form version, which certificate workflow) rather than substantive (whether your device needs a licence at all). Budget for the digitalization learning curve (NSWS onboarding, GMP-portal verification, MSC/NCC resubmission if a prior application is affected) as a real, if modest, planning item.

Element 1 — Device Classification and Pathway Branching

Classification determines everything downstream: whether the manufacturing licence sits with a State Licensing Authority or CDSCO headquarters, whether clinical evidence is expected, and how deep local testing scrutiny runs. Since the 23 October 2025 CDSCO directive, classification itself is also explicitly gated through the Central Licensing Authority for Class A/B and IVD devices before any State Licensing Authority may act — self-classification against an unpublished or assumed category is now an explicit compliance risk, not just an administrative shortcut.

The single most consequential structural correction for a page like this one: unlike domestic manufacturing licensing — where Class A/B routes to a State Licensing Authority and Class C/D routes to CDSCO headquarters — every import licence application, regardless of class, is reviewed and granted centrally by CDSCO's Central Licensing Authority. There is no state-level import review lane at any risk class. Sources that describe Class A/B import applications as going to a "State Licensing Authority" are describing the domestic-manufacturing pathway, not the import pathway that applies to a foreign manufacturer working through an Authorised Agent — a distinction easy to blur and consequential to get wrong when planning which authority to engage.

If a product does not appear on CDSCO's published classification list, the Authorised Agent must first request a classification determination from the CLA before any licence application can proceed — budget 4–8 weeks for this step, and note that the October 2025 directive makes this step mandatory in practice, not optional, for Class A/B and IVD products that are not clearly pre-classified.

Element 2 — License-Holder Logic: The Indian Authorised Agent and Form MD-15

This is India's defining structural fact, and it places India firmly in the "mandatory local persons hold the certificate" camp rather than the "overseas company can retain control" model seen in the EU (Authorised Representative acting as an agent for a manufacturer-held CE certificate) or in Japan's D-MAH alternative. A foreign manufacturer cannot hold an Indian import licence directly, under any pathway, at any risk class.

• Form MD-15 — the import licence — is issued in the Authorised Agent's name, not the foreign manufacturer's. The manufacturer is identified on the licence as the manufacturing site, but the Authorised Agent is the legal licence holder, the entity CDSCO corresponds with, and the entity that bears direct regulatory accountability for the product in India.
• The Authorised Agent must itself hold, or be capable of holding, Form MD-14/MD-15-track credentials — in practice, this generally means an India-registered legal entity with the operational capacity to manage import documentation, warehousing, distribution licensing (MD-42, see Element 4), and post-market obligations.
• There is no D-MAH-style alternative in India the way there is in Japan, and no Authorised Representative model that leaves certificate ownership with the manufacturer the way the EU MDR does — this is the sharpest Europe-vs-Asia structural divide the owner logic behind this content standard calls out, and India sits firmly on the "mandatory local persons hold the certificate" side of that line, alongside most of Southeast Asia.

Decision-grade options for foreign manufacturers

Switching mechanics

Because Form MD-15 is held by the Authorised Agent as a matter of law — not merely as a matter of administrative convenience — changing agents in India is structurally difficult regardless of which of the three models above was chosen. The outgoing agent must cooperate in a change/transfer application (or the manufacturer must file a fresh MD-14/MD-15 application through a new agent from scratch), and imports are suspended during the transition window in either case. This is materially harder to reverse than Japan's D-MAH switching (where the manufacturer itself owns the certificate) and structurally comparable to — arguably worse than — a distributor-held MAH scenario in Japan or Korea, because India offers no certificate-retention alternative at all. Contracts must therefore explicitly address, before signing: (1) ownership and custody of the underlying technical dossier and data package; (2) the outgoing agent's contractual obligation to cooperate with a change-of-agent filing; (3) inventory, adverse-event-history, and complaint-record handover terms; and (4) a defined notice period long enough to overlap a new agent's onboarding with the old agent's continued compliance duties.

Element 3 — License Validity and Review-Timeline Ranges

Why the official target and the real-world figure diverge so sharply for Class C/D: CDSCO's 45-working-day statutory clock measures only the active review period once a complete dossier is accepted — it does not absorb classification-determination delays, multiple additional-information query rounds (routine for Class C/D and effectively unavoidable for a first-time applicant), local BIS/NABL testing scheduling, or apostille-chain preparation. Practitioners consistently report that treating CDSCO's statutory target as the planning baseline for Class C/D is the single most common cause of blown India launch timelines; 18–24 months should be the realistic planning floor for Class C, and 24–36 months for Class D, with the 2024–2026 digitalization push (NSWS, GMP portal, auto-issued certificates) plausibly compressing the administrative-overhead portion of this timeline but not yet demonstrated to compress CDSCO's core technical-review bottleneck. 【待核验：NSWS 数字化对实际审评周期的量化压缩效果，本轮未能找到官方或第三方发布的前后对比数据，仅有制度上线事实,压缩效果为推断】

Element 4 — Authorised Agent In-Country Obligations

Holding Form MD-15 is not a one-time filing event; it is a continuing operational role for as long as the product remains on the Indian market:

Practically: the Authorised Agent relationship is not a mailbox function. An agent that under-invests in adverse-event monitoring, mishandles a supplementary-information response, or lets the retention fee lapse creates real regulatory exposure for the foreign manufacturer that has no direct standing to fix the problem itself — reinforcing why the agent-selection and contract-structuring decisions in Element 2 carry outsized weight in India specifically.

Element 5 — Fee Model: Official CDSCO Fee Schedule (Second Schedule, MDR 2017)

India's government fees are, in absolute terms, modest relative to most of the total cost of India market entry — the real cost drivers are local testing, notarization/apostille logistics, agent/consulting fees, and any triggered clinical investigation, not the CDSCO fee line itself. The table below reproduces the official Second Schedule fee amounts, fetched directly from CDSCO's own published fee document.

Full-project cost estimate — government fee vs. total realistic budget

The strategic reading of this table: CDSCO's own government fee is rarely the budget-driving line item — it is dwarfed by local testing, consulting, and (where triggered) clinical investigation costs. Manufacturers who anchor India cost planning on the government fee schedule alone consistently under-budget the project by an order of magnitude.

Element 6 — Registration Forms: Import, Manufacturing, and Test Licences

All of the above are now filed predominantly through the NSWS portal (live since 1 January 2024) rather than the legacy cdscomdonline system for most MDR 2017 activities, though the legacy portal remains a reference source for historical filings and fee documentation.

Element 7 — Special Requirements

Labeling: MDR 2017 now stands alone, post-Legal Metrology carve-out

For years, foreign manufacturers faced a genuine dual-compliance headache: medical-device labels arguably had to satisfy both MDR 2017's Chapter VI labeling requirements and the separate Legal Metrology (Packaged Commodities) Rules that govern most other packaged consumer goods in India (font-size minimums, declaration placement, MRP display rules, and so on) — with the two rule-sets not always aligned. The Legal Metrology (Packaged Commodities) Amendment Rules, 2025, effective 23 October 2025, resolved this: a fresh proviso carves "packages containing medical devices" out of Legal Metrology's declaration rules, making MDR 2017 the sole governing framework for what must appear on a medical-device label and how. Legal Metrology declarations that still apply — customer-care contact details, country of origin, MRP — may now be placed anywhere on the package, and font-size/legibility is judged against MDR 2017's own "clearly visible" standard rather than Legal Metrology's specific numeral-size table. Manufacturers can no longer separately seek a Legal Metrology waiver for a CDSCO-regulated device, because Legal Metrology no longer governs that content at all.

• Language: English is an official language of India and remains the standard language for labels and IFUs; MDR 2017 does not impose a Hindi or regional-language mandate the way some Southeast Asian jurisdictions require local-language labeling.
• Sterile vs. non-sterile: sterile devices carry additional dossier expectations (sterilization validation data) and additional label content (sterilization method, sterility indicator); non-sterile devices in Class A fall under the lighter registration-only track described in Element 1.
• BIS standards: certain device categories — historically including sphygmomanometers, digital thermometers, and glucometers among others — are subject to mandatory BIS certification (BIS Certification Scheme) independent of, and not waived by, CDSCO licensing or any foreign certificate; each import shipment in a BIS-mandated category must independently meet current BIS standards. 【待核验：本轮未重新核实BIS强制认证的当前完整品类清单，此清单随BIS通知定期更新，建议下单前查询BIS官网最新目录】
• UDI: as of this rebuild, India has not implemented a comprehensive, CDSCO-mandated Unique Device Identification system comparable to the US FDA UDI or EU MDR UDI frameworks; UDI remains on the regulatory reform agenda rather than a current hard requirement. 【待核验：UDI落地时间表本轮未重新核实,继承自前版本，建议直接向CDSCO或授权代理确认最新进度】

Element 8 — Shortcut Pathways: What FDA/CE/UK/Australia/Canada/Japan Approval Unlocks

MDR 2017's clinical-evaluation provisions give CDSCO's Central Licensing Authority explicit discretion to exempt or abbreviate the Indian clinical-investigation requirement for a device already approved and marketed in a defined set of reference jurisdictions — this is India's actual "reliance" mechanism, and it is narrower and more discretionary than a formal mutual-recognition agreement.

The reference-country test

Quick assessment by certificate

What this actually saves, concretely: for a device with ≥2 years of clean market history in one of the six reference jurisdictions, the practical benefit is avoiding or narrowing a full Indian clinical investigation — a savings that can run into the hundreds of thousands of dollars and 12+ months for a Class D device, per the Element 5 cost table. What it does not touch: the Authorised Agent structure (Element 2), local BIS/NABL testing (Element 7), the classification and CLA review process itself (Element 1), or the fee schedule (Element 5) — all of which apply identically whether or not a reference-country exemption is granted. 【待核验：本条款在MDR 2017中的确切条文编号本轮通过多个二手咨询源交叉确认了条件内容(二年上市史+CLA满意度+六国清单)，但未独立核实精确的Rule/Schedule条款号，建议正式申报前请代理核对具体条文引用】

IVD-Specific Requirements

SaMD, AI, and Digital Health Requirements

• 21 October 2025 — CDSCO's Draft Guidance Document on Medical Device Software is the first dedicated framework language distinguishing SiMD (Software in a Medical Device) — software embedded in or driving a hardware device — from SaMD (Software as a Medical Device) — standalone software performing a medical purpose independently, including AI-powered radiology tools, computer-aided detection software, and mobile applications intended to monitor or analyze medical conditions.
• Risk-based classification for SaMD follows the same First Schedule Class A–D structure used for hardware devices, driven by two factors: the significance of the information the software provides, and the seriousness of the healthcare situation it addresses — software playing a direct role in diagnosis or treatment decisions in critical clinical scenarios is likely to land in Class C or D.
• The Draft Guidance does not create new statutory requirements — CDSCO's own framing is that it clarifies how existing MDR 2017 provisions apply to software products, addressing genuine prior uncertainty at the intersection of digital health and device regulation rather than introducing a parallel regulatory track.
• Practical implication for foreign SaMD/DTx applicants: expect the same Authorised Agent, Form MD-14/MD-15, and classification-first process described throughout this page to apply to standalone software exactly as it applies to hardware — there is, as of this rebuild, no accelerated or software-specific fast lane comparable to Japan's DASH for SaMD program. Budget a classification-first conversation with CDSCO or an experienced agent before committing to a regulatory strategy for an AI-driven diagnostic or monitoring product, since the Class A–D placement materially changes both the licensing authority and the evidence bar. 【待核验：该草案指南截至本轮核验仍为"Draft"（未定稿），最终定稿版本及是否引入软件专属流程需持续跟踪】

Registration Dossier Requirements

• Administrative documents:
  • Form MD-14 (import licence application), completed via NSWS/SUGAM
  • Authorised Agent's business registration and licensing credentials
  • Authorization letter from the foreign manufacturer (notarized and apostilled, or consularized for non-Hague-member origin countries)
  • Certificate of Free Sale (CFS) or equivalent from the manufacturer's home-country government (notarized and apostilled)
  • Home-country manufacturing licence/GMP certificate (notarized and apostilled)
• Technical documents:
  • Product description, intended use, and technical specifications
  • Performance and safety test reports (IEC/ISO international standards or accepted Indian equivalents)
  • Risk-management file (ISO 14971)
  • Biocompatibility report (ISO 10993, where applicable)
  • Clinical evidence — literature review, reference-country marketing history under Element 8, or a full clinical investigation report for Class C/D devices without a qualifying exemption
  • Software documentation (IEC 62304, where applicable) — see SaMD section above
  • Shelf-life/stability data
• Local test reports: Class C/D devices typically require testing at a BIS- or NABL-accredited Indian laboratory, or CDSCO-accepted overseas laboratory test data where policy currently permits; BIS-mandated categories require additional BIS compliance certification independent of the CDSCO dossier.
• Labeling and IFU: English-language label specimen meeting the MDR 2017 Chapter VI elements in Element 7, plus the Instructions for Use.
• QMS documentation: ISO 13485-conformant quality manual and manufacturing-site information; GMP certificate, now verifiable through the centralized online GMP portal launched February 2025.
• IVD-specific additions: IVD-rule-set classification confirmation and India-specific clinical-evaluation data where a reference-country exemption is not available (see IVD section above).

Post-Market Surveillance and the Materiovigilance Programme of India (MvPI)

• Materiovigilance Programme of India (MvPI): operated by the Indian Pharmacopoeia Commission (IPC), MvPI is India's national medical-device adverse-event monitoring system, revised 4 November 2024 with an expanded reporting form and, from March 2025, a dedicated expert committee covering cardiology, neurology, and radiology device categories.
• Adverse-event reporting timeline: death or serious injury must be reported to CDSCO within a defined statutory window (commonly cited at 30 days from the Authorised Agent becoming aware of the event); submission runs through the SUGAM/NSWS online system.
• Recall rules: recalls must be reported to and publicized by CDSCO, classified Voluntary or Mandatory; multi-state distribution requires coordinating recall execution with each affected state's drug-control authority — a meaningfully heavier coordination burden than a single-authority recall system.
• Periodic reporting and PMS plans: mandatory for Class C/D devices under MDR 2017; enforcement intensity has historically been uneven but is visibly tightening given the 2024–2025 MvPI reforms.
• Change management: the Authorised Agent must classify each product change correctly between a routine notification and a formal change application to CDSCO — under-reporting significant design, specification, or manufacturing-site changes is a recognized, avoidable compliance-risk pattern.

Import and Customs Requirements

• Import licence: a valid Form MD-15 must be in place before import; individual shipments do not require separate per-shipment approval once the licence is active — customs clearance proceeds against the licence number.
• Customs declaration: HS code declaration is required; the MD-15 licence number must accompany the customs declaration; BIS-mandated categories may require BIS certification documentation at customs, and some devices require import inspection/quarantine certificates.
• Duties and taxes: imported devices are subject to basic customs duty plus GST, with the combined effect materially shaping landed-cost competitiveness against domestic manufacturers benefiting from Make in India/PLI incentives. 【待核验：具体关税与GST税率随年度预算(Union Budget)调整，本页继承自前版本(核验于2026-07-03)的税率区间本轮未重新核实，建议下单前以最新海关税则为准】
• Labeling at the point of entry: English-language MDR 2017-compliant labeling, per Element 7, is required at the point of market entry, not merely at the point of final sale.

Price Control: NPPA and the National List of Essential Medical Devices

Price control is a distinctly India-specific commercial risk that has no close analogue in most of the rest of Asia covered on this site, and it can compress margins on an otherwise fully compliant, fully licensed device with no warning tied to the regulatory approval process itself.

• National Pharmaceutical Pricing Authority (NPPA) sets ceiling prices for devices listed in the National List of Essential Medical Devices, incorporated into Schedule-I of the Drugs (Prices Control) Order, 2013.
• Coronary stents: ceiling prices are revised periodically against the Wholesale Price Index; the most recent cited revision sets Bare Metal Stents (BMS) at approximately ₹10,762 per unit and Drug Eluting Stents (DES, including bioresorbable scaffolds) at approximately ₹39,186 per unit, effective from April 2026.
• Knee implants: the ceiling-price mechanism for orthopedic knee-replacement implants, first notified in 2017, has been repeatedly extended — most recently through November 2026.
• Practical implication: price control is category-specific, not device-class-specific — a fully licensed Class D device can still land in an NPPA-controlled category if it falls within the National List of Essential Medical Devices' scope. Manufacturers of coronary, orthopedic, and other historically price-controlled categories should model NPPA exposure before, not after, committing to India registration spend, since price-control status is set independently of, and can be added to at any time regardless of, the CDSCO licensing outcome.

Market Access Channels

• Public hospitals / government procurement: central procurement runs through HLL Lifecare/CMSS (Central Medical Services Society); individual state governments run independent tenders; intense price competition generally makes this channel unsuitable as a first entry point for premium imported devices.
• High-end private hospitals: large chains — Apollo, Fortis, Max, Manipal, Narayana Health, Aster — remain the primary channel for imported premium devices, with independent procurement committees and comparatively shorter decision cycles than government tenders.
• Diagnostic chains: Dr. Lal PathLabs, Metropolis, Thyrocare, and regional networks drive IVD and diagnostic-equipment volume, particularly relevant given the IVD-specific fee and evidence considerations above.
• Distribution network: India's distribution hierarchy (national distributor → regional distributor → hospital/clinic) is complex and channel-management-intensive; medical-device distributor association resources can help identify qualified partners.
• Government tenders: state health departments run regular tenders; products must be listed in government procurement catalogues, and price competition is pronounced.

Main Players and Channel Map

Market Entry Strategy and Key Risks

• Confirm classification through the CLA, not by self-assessment, especially for Class A/B and IVD products — the 23 October 2025 directive makes this an explicit compliance checkpoint, not just good practice.
• Choose the Authorised Agent model deliberately before signing any distribution agreement — decide whether an own-subsidiary, distributor-affiliated, or independent third-party agent structure best protects long-term licence control, since switching later is structurally difficult regardless of the model chosen (Element 2).
• Build the reference-country exemption case early if eligible — a device with ≥2 years' clean market history in the US, EU, UK, Australia, Canada, or Japan should have that evidence packaged and CLA-facing from the start of dossier preparation, not raised reactively mid-review (Element 8).
• Plan NPPA price-control exposure before committing registration spend, particularly for coronary, orthopedic, and other historically controlled categories (see Price Control section).
• Budget the realistic timeline, not the statutory target: 18–24 months for Class C, 24–36 months for Class D, plus a 2–4 month apostille/notarization lead time that should start in parallel with, not after, dossier preparation.
• Key risks:
  • Agent lock-in risk: the single most India-specific structural risk on this page — no certificate-retention alternative exists, and changing agents suspends imports during the transition.
  • Price-control risk: NPPA can add new categories to the National List of Essential Medical Devices independent of the CDSCO approval timeline.
  • Digitalization-transition risk: applicants with filings pending under the pre-2024/pre-2025 portal and certificate workflows (NSWS transition, MSC/NCC auto-issuance) may need to refile — confirm current filing-system status with the Authorised Agent before assuming an in-flight application's status.
  • Query-driven delay risk: each CDSCO additional-information round typically adds 3–6 months; incomplete or poorly localized technical documentation is the most controllable driver of this risk.
  • Multi-state coordination risk: recalls, and in some cases distribution licensing, require coordinating across each relevant state's drug-control authority, not a single national point of contact.
• Practical tips:
  • Initiate the apostille/notarization chain at project kickoff, not after dossier drafting is complete.
  • Verify an Authorised Agent candidate's active CDSCO project history where publicly checkable, as part of due diligence before contracting.
  • Track CDSCO circulars directly (or through a specialist agent) given the pace of 2024–2026 procedural change — NSWS, GMP portal, and MSC/NCC workflow changes have each required affected applicants to take fresh action, not merely wait.

Frequently Asked Questions

Who regulates medical devices in India?

The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), regulates medical devices under the Medical Device Rules 2017. CDSCO acts as the Central Licensing Authority for all import licences (every risk class) and for Class C/D domestic manufacturing licences; State Licensing Authorities handle only Class A/B domestic manufacturing licences.

Is a local representative mandatory to sell medical devices in India?

Yes, without exception. A foreign manufacturer cannot hold an Indian import licence directly under any pathway or risk class. It must appoint an India-registered Authorised Agent, who files Form MD-14 and, once approved, holds the resulting Form MD-15 import licence in its own name. There is no D-MAH-style or EU-style Authorised-Representative alternative that leaves certificate ownership with the manufacturer.

Has India completed its transition to mandatory device registration?

Yes — as of 1 October 2023, all previously "non-notified" Class C and Class D devices were brought under mandatory CDSCO licensing, completing the phased rollout that began with MDR 2017's 2017–2018 introduction and GSR 102(E)'s February 2020 scope expansion. Virtually every device category is now licensed except Class A non-sterile, non-measuring devices, which remain under a lighter registration-only track. The live regulatory story since then has shifted from "will this device need a licence" to digitalization and enforcement-tightening — see the 2024–2026 developments section above.

How long does an India import licence actually take?

Realistic ranges, against CDSCO's own 30/45-working-day statutory targets: 2–6 months for Class A/B, and 12–36 months for Class C/D — with 18–24 months as a reasonable Class C planning floor and 24–36 months for Class D. Each additional-information query round typically adds 3–6 months, and the apostille/notarization chain for foreign documents should be started 2–4 months ahead of dossier submission.

Does an existing FDA, CE, UK, Australian, Canadian, or Japanese approval speed up Indian registration?

Partially, and only for clinical evidence. MDR 2017 lets CDSCO's Central Licensing Authority exempt or abbreviate the Indian clinical-investigation requirement for a device with at least two years' marketing history in the US, EU, UK, Australia, Canada, or Japan, subject to the CLA being satisfied with the submitted safety and performance data. It does not waive the Authorised Agent requirement, local BIS/NABL testing, BIS mandatory certification, MDR 2017 labeling, or the classification/licensing process itself. A Chinese NMPA approval is not a recognized reference-country credential under this mechanism.

Does the MD-15 import licence expire?

No — Form MD-15 is valid in perpetuity once granted. However, the Authorised Agent must pay a retention fee every 5 years; missing this payment triggers a 2%-per-month late surcharge within a 90-day grace window, and non-payment past that window results in the licence being deemed cancelled.

What changed in India's medical-device regulation most recently?

The most consequential 2024–2026 developments are procedural and digital rather than a further expansion of licensing scope (which was completed by the 1 October 2023 deadline): the NSWS portal replaced most legacy MDR 2017 filings from January 2024; a centralized GMP certificate portal launched February 2025; Market Standing/Non-Conviction Certificates moved to auto-generated digital issuance in April 2025; a 23 October 2025 directive tightened CLA classification gatekeeping for Class A/B/IVD devices; the same date's Legal Metrology carve-out resolved years of dual-labeling-compliance ambiguity; and CDSCO issued its first Draft Guidance on Medical Device Software on 21 October 2025, formally distinguishing SaMD from SiMD.

What does the Materiovigilance Programme of India (MvPI) require?

MvPI, run by the Indian Pharmacopoeia Commission, is India's national medical-device adverse-event monitoring system. The Authorised Agent bears the statutory obligation to report death or serious injury to CDSCO within a defined window via the SUGAM/NSWS system. The reporting form was revised on 4 November 2024, and a dedicated expert committee covering cardiology, neurology, and radiology device categories was established in March 2025, signaling intensified scrutiny of high-consequence device categories specifically.

Official Sources and Verification Dates

• CDSCO — Medical Device & Diagnostics official portal (official, directly fetched): https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/Medical-Device-Diagnostics/ (fetched and confirmed 2026-08-17; classification, MD-14/MD-15 structure, and 2024–2026 update headlines cross-checked here)
• CDSCO/legacy portal — Official Second Schedule fee document (official, directly fetched): https://cdscomdonline.gov.in/NewMedDev/resources/app_srv/NMD/global/helpfiles/nmd_fee.pdf (fetched and confirmed 2026-08-17; all fee figures in Elements 5, 3, and 6 sourced directly from this primary document)
• CDSCO — Regulatory pathway for medical devices under MDR 2017 (official PDF, referenced via search): https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/medical-device/RegulatoryMDR-2017.pdf (accessed 2026-08-17)
• Medical Device Rules, 2017 (official text, referenced via search): https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2022/m_device/Medical%20Devices%20Rules,%202017.pdf (accessed 2026-08-17)
• CliniExperts — Procedure for CDSCO licence mandate on Class C/D non-notified devices (secondary): https://cliniexperts.com/complete-procedure-to-meet-the-cdsco-license-mandate-of-class-c-d-non-notified-medical-devices/ (accessed 2026-08-17; 1 October 2023 deadline cross-checked here)
• CliniExperts — CDSCO NSWS portal launch (secondary): https://cliniexperts.com/regulatory-update/cdsco-launched-national-single-window-system-nsws-portal/ (accessed 2026-08-17)
• CliniExperts — CDSCO auto-generated MSC/NCC workflow (secondary): https://cliniexperts.com/regulatory-update/cdsco-transitions-to-automated-online-system-for-issuance-of-msc-and-ncc-for-medical-devices/ (accessed 2026-08-17)
• Pacific Bridge Medical — India Medical Device Regulations: A 2025 Update (secondary): https://www.pacificbridgemedical.com/publication/india-medical-device-regulations-2025-update/ (accessed 2026-08-17)
• Morulaa HealthTech — CDSCO's new directive on Class A, B & IVD device licensing (secondary): https://morulaa.com/news-india-cdsco-medical-device-licensing-2025/ (accessed 2026-08-17; 23 October 2025 CLA classification directive cross-checked here)
• Mondaq / IndiaLaw — Legal Metrology (Packaged Commodities) Amendment Rules 2025 (secondary): https://www.mondaq.com/india/healthcare/1698236/medical-devices-step-out-of-legal-metrology-packaged-commodities-shadow-2025-amendment-ends-labelling-confusion, https://www.indialaw.in/blog/legal-metrology/medical-devices-exit-legal-metrology-labelling-rules/ (accessed 2026-08-17)
• Business Standard — CDSCO centralizes GMP issuance with new online portal, February 2025 (secondary): https://www.business-standard.com/health/cdsco-centralises-gmp-issuance-and-verification-with-new-online-portal-125022801208_1.html (accessed 2026-08-17)
• Lexology — CDSCO's Draft Guidance on Medical Device Software (secondary): https://www.lexology.com/library/detail.aspx?g=b42b5638-1491-401d-99b3-16b5b0847020 (accessed 2026-08-17; October 2025 SaMD/SiMD guidance cross-checked here)
• Cyril Amarchand Blogs — Medical Device As Software: Has CDSCO Guidance Changed the Rules? (secondary): https://corporate.cyrilamarchandblogs.com/2026/01/medical-device-as-software-has-cdsco-guidance-changed-the-rules/ (accessed 2026-08-17)
• Medical Buyer / Medical Dialogues — NPPA coronary stent price revision, April 2026 (secondary): https://medicalbuyer.co.in/nppa-caps-coronary-stent-prices-bms-priced-at-%E2%82%B910692-69-des-at-%E2%82%B938933-14/, https://medicaldialogues.in/news/industry/medical-devices/nppa-revises-coronary-stent-prices-des-at-rs-39186-and-bms-at-rs-10762-from-april-2026-168192 (accessed 2026-08-17)
• Business Standard — NPPA extends knee implant price ceiling to November 2026 (secondary): https://www.business-standard.com/industry/news/nppa-extends-knee-implant-price-ceiling-november-2026-125111701358_1.html (accessed 2026-08-17)
• NHSRC / Indian Pharmacopoeia Commission — Materiovigilance Programme of India (secondary/quasi-official): https://nhsrcindia.org/hc-technology/materiovigilance-programme-of-india, https://ipc.gov.in/mandates/materiovigilance-programme-of-india-mvpi/8-category-en/432-launch-of-materiovigilance-programme-of-india-mvpi.html (accessed 2026-08-17; November 2024 form revision and March 2025 expert committee cross-checked here)
• Pharmadocx Consultants — CDSCO licence retention fee and payment reminder (secondary): https://pharmadocx.com/cdsco-license-retention-fee-for-maintaining-license-validity/, https://pharmadocx.com/cdsco-license-retention-fee-payment-reminder/ (accessed 2026-08-17; 5-year retention cycle and 2%/month late-fee mechanics cross-checked here)
• Nishith Desai Associates — Analysis of Medical Devices Rules, 2017 (secondary, legal-analysis firm): https://www.nishithdesai.com/fileadmin/user_upload/pdfs/NDA%20Hotline/Analysis_of_Medical_Devices_Rules-2017.pdf (accessed 2026-08-17; 1 January 2018 effective date cross-checked here)
• Reghelps / Asia Actual — Clinical investigation exemption for reference-country-approved devices (secondary): https://www.reghelps.com/clinical-investigation-for-medical-devices/, https://asiaactual.com/india/medical-device-registration/ (accessed 2026-08-17; six-jurisdiction reference-country list and 2-year marketing-history threshold cross-checked here)
• National Pharmaceutical Pricing Authority (NPPA), official: https://www.nppaindia.nic.in, https://nppa.gov.in (accessed 2026-08-17)
• Verification date: 2026-08-17

Items flagged for further verification (【待核验】)

• The exact statutory Rule/Schedule citation for the reference-country clinical-investigation exemption in Element 8 — the substantive condition (≥2 years' market history in Australia/Canada/EU/Japan/UK/USA, subject to CLA discretion) is well cross-referenced across multiple secondary regulatory-consultancy sources, but the precise MDR 2017 rule number was not independently confirmed against the primary Rules text during this pass.
• Whether the 2024–2026 digitalization push (NSWS, GMP portal, auto-issued certificates) has measurably compressed real-world Class C/D review timelines — this rebuild documents the systems going live, but no official or independent before/after timeline benchmark was found; the practical-timeline ranges in Element 3 are held at their pre-digitalization levels pending such evidence.
• The current, complete list of BIS-mandatory-certification device categories — this list is updated by periodic BIS notification and was not independently re-verified in this pass; the prior version's approximate category count is carried forward with a verification flag.
• India's UDI implementation timeline — carried forward from the prior version of this page without fresh re-verification this round; confirm current status directly with CDSCO or an Authorised Agent before relying on it.
• Current basic customs duty and GST rates applicable to imported medical devices — these are set by the annual Union Budget and were not re-verified this round; the prior version's rate range (10–25% customs duty, 12–18% GST) is carried forward as a directional reference only.
• The scope of clinical-evaluation exemption specifically for new IVD devices under the reference-country mechanism — secondary sources suggest India-specific clinical data is more consistently requested for new IVDs than for general devices even where a foreign approval exists, but this was not independently confirmed against primary CDSCO IVD guidance in this pass.